Rodríguez-Calvillo, Javier A., Lana, Alberto, Cueto, Antonio, Markham, Wolfgang A. and López, M. L. (Maria Luisa). (2011) Psychosocial factors associated with the prescription of generic drugs. Health Policy, Vol.101 (No.2). pp. 178-184. ISSN 0168-8510

Full text not available from this repository.

Abstract

Objective: To evaluate factors associated with "Generic drug prescription" (GDP) behaviour in Spain using the ASE (Attitude, Social Influence, Self-Efficacy) Model. Methods: General Practitioners were sent a validated and anonymous questionnaire measuring the ASE and Motivation variables for GDP and their generic drug prescription percentage. Most (n = 486: 61.98%) responded to this cross-sectional survey. The mean scores and the 95% confidence intervals (95% Cl) were calculated. A binary logistic regression was used to identify the variables that best predict GDP behaviour. Results: The main advantages and motivations for GDP were "saving money" and "protecting professional ethics". The greatest social influences were "doctors personal preferences" and "authorities' pressure". GDP accounted for a scarce 15% of the total prescription. ASE and Motivation items were the best predictors: they explain 25% of being a 'high prescriber'. The highest prescribers were paediatricians (OR = 5.07), workers in rural settings (OR = 3.68) and professionals with high Motivation (OR = 1.17) and Attitude (OR = 1.11) scores. Conclusions: GDP percentage is very low compared with other countries. Interventions to modify the Attitudes of Primary Care doctors towards generic drugs should be implemented. Better informed patients, longer doctor appointment times and more varied dosage forms of generic drugs would also facilitate improvements in GDP

Item Type:	Journal Article
Subjects:	B Philosophy. Psychology. Religion > BF Psychology H Social Sciences > HM Sociology R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Social Sciences > School of Health and Social Studies
Library of Congress Subject Headings (LCSH):	Drugs -- Prescribing -- Psychological aspects, Drugs -- Prescribing -- Social aspects, Physicians (General practice) -- Attitudes, Generic drugs
Journal or Publication Title:	Health Policy
Publisher:	Elsevier Ireland Ltd.
ISSN:	0168-8510
Date:	July 2011
Volume:	Vol.101
Number:	No.2
Page Range:	pp. 178-184
Identification Number:	10.1016/j.healthpol.2010.10.015
Status:	Peer Reviewed
Publication Status:	Published
Funder:	Asturias (Spain)
Grant number:	CN-04-269C (Asturias)
References:	[1] Organisation for Economic Co-operation and Development. OECD Health Data 2009: statistics and indicators for 30 countries. Paris: OECD; 2009. [2] World Health Organization. Promoting rational use of medicines: core components – WHO Policy Perspectives on Medicines, No. 05. Geneva: WHO Press; 2002. [3] Ministerio de Sanidad y Consumo. Especialidades farmacéuticas genéricas y medicamentos huérfanos. Información Terapéutica del Sistema Nacional de Salud 2006;30:78–9. [4] Okechukwu I, Bennett K, Feely J. General practitioners’ ranking of evidence-based prescribing quality indicators: a comparative study with a prescription database. British Journal of Clinical Pharmacology 2006;62:218–24. [5] Federación Empresarial de Farmacéuticos Espa˜ noles. Observatorio del medicamento y notas de prensa – Recopilatorio 2007. Madrid: Federación Empresarial de Farmacéuticos Espa˜noles; 2008. [6] Ajzen I. The theory of planned behaviour. Organizational Behavior and Human Decision Processes 1991;50:179–211. [7] Davis DA, Taylor-Vaisey A. Translating guidelines into practice: a systematic review of theoretical concepts, practical experience, and research evidence in the adoption of clinical practice guidelines. Canadian Medical Association Journal 1997;157:408–16. [8] Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. Canadian Medical Association Journal 1995;153:1423–31. [9] Perkins MB, Jensen PS, Jaccard J, Gollwitzer P, Oettingen G, Pappadopulos E, et al. Applying theory-driven approaches to understanding and modifying clinicians’ behavior: what do we know? Psychiatric Services 2007;58:342–8. [10] US Public Health Service. Mental health: a report of the Surgeon General. Washington, DC: Department of Health and Human Services; 1999. [11] Sturm H, Austvoll-Dahlgren A, Aaserud M, Oxman AD, Ramsay C, Vernby A, et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database of Systematic Reviews 2007;18:CD006731. [12] De Vries H, Mudde AN, Dijkstra A, Willemsen MC. Differential beliefs, perceived social influences, and self-efficacy expectations among smokers in various motivational phases. Preventive Medicine 1998;27:681–9. [13] DeVries H,MuddeAN. Predicting stage transitions for smoking cessation applying the attitude social influence efficacy model. Psychology & Health 1998;13:369–85. [14] Bolman C, de Vries H, Mesters I. Factors determining cardiac nurses’ intentions to continue using a smoking cessation protocol. Heart & Lung 2002;31:15–24. [15] Bunce D, Birdi KS. The theory of reasoned action and theory of planned behaviour as a function of job control. British Journal of Health Psychology 1998;3:265–75. [16] Edwards HE, Nash RE, Najman JM, Yates PM, Fentiman BJ, Dewar A, et al. Determinants of nurses’ intention to administer opioids for pain relief. Nursing & Health Sciences 2001;3:149–59. [17] Limbert C, Lamb R. Doctors’ use of clinical guidelines: two applications of the theory of planned behaviour. Psychology, Health and Medicine 2002;7:301–10. [18] Walker AE, Grimshaw JM, Armstrong EM. Salient beliefs and intentions to prescribe antibiotics for patients with a sore throat. British Journal of Health Psychology 2001;6:347–60. [19] Rodríguez J, Prescripción de medicamentos genéricos y sus determinantes psicosociales en facultativos de atención primaria [dissertation]. Oviedo: Servicio de Publicaciones, Universidad de Oviedo; 2006. [20] de Vries H, Mesters I, Riet JV, Willems K, Reubsaet A. Motives of Belgian adolescents for using sunscreen: the role of action plans. Cancer Epidemiology, Biomarkers and Prevention 2006;15:1360–6. [21] Broekhuizen K, van Poppel MN, Koppes LL, Brug J, van Mechelen WA. Tailored lifestyle intervention to reduce the cardiovascular disease risk of individuals with familial hypercholesterolemia (FH): design of the PRO-FIT randomised controlled trial.BMCPublic Health 2010;15(10):69. [22] Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiology Drug and Safety 2005;14:341–8. [23] Kjoenniksen I, Lindbaek M, Granas AG. Patients’ attitudes towards and experiences of generic drug substitution in Norway. Pharmacy World and Science 2006;28:284–9. [24] Ping CC, Bahari MB, Hassali MA. A pilot study on generic medicine substitution practices among community pharmacists in the State of Penang, Malaysia. Pharmacoepidemiology Drug and Safety 2008;17:82–9. [25] Ringuier R, Rouquette A, Dagorne C, Garnier F, Fanello S. Fifty years old and more patients’ attitudes towards and experiences of generic substitution of prescription medicines. Therapie 2008;63: 11–7. [26] Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Archives of Internal Medicine 2006;13(166): 332–7. [27] Krusemark EA, Keith Campbell W, Clementz BA. Attributions, deception, and event related potentials: an investigation of the self-serving bias. Psychophysiology 2008;45:511–5. [28] Vallès JA, Barreiro M, Cereza G, Ferro JJ, Martínez MJ, Escribà JM, et al. A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice. Health Policy 2003;65:269–75. [29] Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Medicine 2007;4:e283. [30] Fowkes FG. Doctors’ knowledge of the costs of medical care. Medical Education 1985;19:113–7. [31] Wadland WC, Farquhar L, Priester F, Oberst K, Weismantel DP. Increasing generic prescribing: a resident educational intervention. Family Medicine 2005;37:259–64. [32] World Health Organization. Guidelines on the use of International Nonproprietary Names (INNs) for pharmaceutical substances. Geneva: WHO Press; 1997. WHO/PHARM S/NOM 1570. [33] Shrank WH, Stedman M, Ettner SL, DeLapp D, Dirstine J, Brookhart MA, et al. Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use. Journal of General Internal Medicine 2007;22:1298–304. [34] Vancelik S, Beyhun NE, Acemoglu H, Calikoglu O. Impact of pharmaceutical promotion on prescribing decisions of general practitioners in Eastern Turkey. BMC Public Health 2007;7:122. [35] Figueiras A, Caama˜no F, Gestal Otero JJ. Incentives for doctors from the pharmaceutical industry: ethical problems, limits, and alternatives. Gaceta Sanitaria 1997;11:297–300. [36] Muijrers PE, Grol RP, Sijbrandij J, Janknegt R, Knottnerus JA. Differences in prescribing between GPs: impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives. Family Practice 2005;22:624– 30. [37] Espigares Arroyo M, Montes Salas G, Altimiras Roset J, Iglesias Sánchez JM, Brioso Jerez F. Predictive factors of drug prescription: profile of the overprescribing physician. Gaceta Sanitaria 1994;8:25–9. [38] Cummings SM, Savitz LA, Konrad TR. Reported response rates to mailed physician questionnaires. Health Services Research 2001;35:1347–55. [39] Servicio de Salud del Principado de Asturias (Gerencia). Recursos humanos: características de los médicos de atención primaria. Oviedo: Servicio de publicaciones, SESPA; 2006.
URI:	http://wrap.warwick.ac.uk/id/eprint/38802

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item